Primary plasma cell leukemia: Clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

Leukemia

Volumn 26, Issue 11, 2012, Pages 2398-2405

  Usmani, S Z ^a   Nair, B ^a   Qu, P ^b   Hansen, E ^b   Zhang, Q ^a   Petty, N ^a   Waheed, S ^a   Shaughnessy Jr , J D ^a   Alsayed, Y ^a   Heuck, C J ^a   Van Rhee, F ^a   Milner, T ^a   Hoering, A ^b   Szymonifka, J ^b   Sexton, R ^b   Sawyer, J ^a   Singh, Z ^a   Crowley, J ^b   Barlogie, B ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Gene expression profiling; Myeloma; Plasma cell leukemia; Prognosis; Total therapy

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; INTERLEUKIN 1; LACTATE DEHYDROGENASE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; GENE EXPRESSION PROFILING; HUMAN; LIVER FIBROSIS; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

AGED; CLINICAL PROTOCOLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, PLASMA CELL; MALE; TREATMENT OUTCOME;

EID: 84869079232     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.107     Document Type: Article

References (15)

1. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukemia. Br J Haematol 1994; 88: 754-759.
2. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia: A report on 17 cases. Arch Intern Med 1974; 133: 813-818.
3. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276-2279. (Pubitemid 41510796)
4. Noel P, Kyle RA. Plasma cell leukemia: An evaluation of response to therapy. Am J Med 1987; 83: 1062-1068. (Pubitemid 18098878)
5. Barlogie B, Kyle RA, AnDerson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936. (Pubitemid 46638847)
6. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoetic-cell transplantation for multiple myeloma. N Engl J Med 2003; 354: 1021-1030.
7. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of Total Therapy 3. Br J Haematol 2007; 138: 176-185. (Pubitemid 46978271)
8. Nair B, van Rhee F, Shaughnessy Jr JD, Anaissie E, Szymonifka J, Hoering A et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood 2010; 115: 4168-73.
9. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by Deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284. (Pubitemid 46425864)
10. Bladé J, Samson D, Reece D, Apperley J, Bjö rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123. (Pubitemid 28435189)
11. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, AnDerson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
12. Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Bladé J, Moro MJ et al. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood 1999; 93: 1032-1037. (Pubitemid 29067869)
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Shaughnessy Jr JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 2011; 118: 3512-24.
15. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028. (Pubitemid 44395016)